Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EG MCV4

Next Previous
Drug Profile

EG MCV4

Alternative Names: CRM-197 peptide vaccine; EG-MCV4; Meningococcal conjugate vaccine - EyeGene; Meningococcal(groups A, C, W-135, and Y) conjugate vaccine - EyeGene.

Latest Information Update: 17 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EyeGene
  • Class Conjugate vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Meningococcal infections

Most Recent Events

  • 02 Oct 2025 EyeGene plans a phase II/III trial for Meningococcal infection (IM)in South Korea in October 2025 (NCT07204457 (700387147)
  • 01 Oct 2025 Preclinical trials in Meningococcal infections in South Korea (IM) (EyeGene pipeline, October 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top